Form 4: Daxor CMO John Jefferies Granted Equity

Daxor Corp's Chief Medical Officer, John Jefferies, was granted 2,344 shares of common stock, vesting on November 12, 2025, increasing his beneficial ownership to 17,616 shares.

Summary

• John Jefferies, Chief Medical Officer of Daxor Corp (DXR), was granted 2,344 shares of common stock.
• The transaction date for the grant was November 12, 2025.
• The 2,344 granted shares are scheduled to vest on November 12, 2025.
• Following this transaction, John Jefferies beneficially owns a total of 17,616 shares of Daxor Common Stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: The grant of equity to a Chief Medical Officer aligns management's interests with shareholders, which is generally viewed positively as it incentivizes long-term performance and retention.

Positives

• The grant of equity to the Chief Medical Officer increases insider ownership, aligning management's interests with those of shareholders.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned equity compensation strategy.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

Equity grants to key executives are a standard practice across industries to incentivize performance, retain talent, and align management's long-term interests with shareholder value creation. This particular grant to the Chief Medical Officer of Daxor Corp is consistent with typical executive compensation structures in the biotechnology and medical device sectors.

Stakeholder Impact

• Shareholders: Increased alignment of management's interests with shareholder value due to increased insider ownership.
• Employees: Reinforces the company's commitment to executive compensation and retention through equity incentives.

Next Steps

• The 2,344 granted shares will vest on November 12, 2025.

Key Dates

Keywords

Daxor Corp, DXR, John Jefferies, Chief Medical Officer, Insider Transaction, Equity Grant, Form 4, Beneficial Ownership, Rule 10b5-1